Showing 181–192 of 208 resultsSorted by latest
Pharma & Biotech
The promising results for Scemblix and Iptacopan, in particular, represent significant advancements in their respective therapeutic areas, potentially opening up new revenue streams and strengthening Novartis’ market position.
Abbott Laboratories has built a strong brand reputation and customer loyalty across its diverse product portfolio. In the nutrition segment, the company regained its market leadership position in the U.S. infant formula business, reflecting the trust and confidence of its users and customers in Abbott’s products.
The Prevnar franchise, a significant revenue contributor for Pfizer, faced several challenges. In the U.S. adult market, the catch-up opportunity for Prevnar 20 has been largely exhausted, with a diminishing patient pool and increasing competition expected.
Thermo Fisher Scientific, a leading player in the bioproduction market, faced challenges amidst market volatility in 2023. Despite this, the company remains optimistic about its long-term growth potential.
UnitedHealth Group continues to invest heavily in digital capabilities and artificial intelligence (AI) to enhance customer experiences, improve operational efficiencies, and drive productivity gains.
Regeneron Pharmaceuticals is facing heightened competition in the retinal disease and dermatology sectors, with the introduction of biosimilar alternatives like Lucentis and brolucizumab in the retinal category, and new JAK inhibitors challenging Dupixent in atopic dermatitis.
Johnson & Johnson faces competitive pressures and the loss of exclusivity for several key products, which could impact future revenue growth.
AbbVie’s flagship product, Humira, experienced a substantial operational revenue decline of 40.7% globally, with a full-year decrease of 31.9%.
CVS Healthcare Corp’s $5bn Settlement in Opioid Litigation: Opioid Litigation: In 2023, CVS agreed to pay approximately $5bn to settle lawsuits related to its role in the opioid crisis. The lawsuits alleged that CVS failed to properly monitor and report suspicious orders of prescription opioids, contributing to the nation’s opioid epidemic.
Eli Lilly and Company has recently intensified its commitment to research and development (R&D) activities, evident in a noteworthy 28% surge in R&D expenses. This substantial increase is attributed to the company’s strategic investments in both late-stage assets and early research projects, emphasizing its dedication to addressing unmet medical needs.
The challenges faced with AMG340 highlight the importance of diversifying and strengthening the product pipeline to mitigate risks associated with individual assets.
The company has witnessed a decline in sales of its hepatitis C virus (HCV) drug, particularly with a 1% year-over-year drop in Epclusa/authorized generics sales and a substantial 39% decrease in Harvoni/authorized generics sales.